Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
Thiquynhnga Nguyen,* Song Wen,* Min Gong,* Xinlu Yuan, Dongxiang Xu, Chaoxun Wang, Jianlan Jin, Ligang Zhou Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lig...
Main Authors: | Nguyen T, Wen S, Gong M, Yuan X, Xu D, Wang C, Jin J, Zhou L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-08-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity |
Subjects: | |
Online Access: | https://www.dovepress.com/dapagliflozin-activates-neurons-in-the-central-nervous-system-and-regu-peer-reviewed-article-DMSO |
Similar Items
-
Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
by: Avgerinos I, et al.
Published: (2019-12-01) -
Determining the Role of SGLT2 Inhibition with Dapagliflozin in the Development of Diabetic Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2022-12-01) -
Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study
by: Jaehyun Lim, et al.
Published: (2023-07-01) -
A case report of euglycemic ketoacidosis due to dapagliflozin treatment
by: Murat Çalapkulu, et al.
Published: (2021-03-01) -
SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate
by: Michael S. Balzer, et al.
Published: (2020-11-01)